Major Depressive Disorder Clinical Trial
Official title:
Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21)
The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants. Such perfusion deficits could contribute to antidepressant nonresponse as they would hinder improvements in dorsal system metabolism seen with antidepressant treatment. The objective of the current proposal is to determine if decreased vascular reactivity and frontal hypoperfusion in depressed elders predicts and persists with antidepressant nonremission. The investigators will pursue the primary aim testing the hypothesis that decreased reactivity and hypoperfusion, specifically in the dorsolateral prefrontal cortex and dorsal anterior cingulate cortex, predict antidepressant nonremission. The investigators will enroll 40 depressed elders who will complete clinical, cognitive, and MRI assessments before and after a 12-week open-label antidepressant trial of sertraline.
The long-term goal of this line of research is to determine if in late-life depression
(LLD), cerebrovascular dysregulation is predictive of antidepressant outcomes. The
investigators hypothesize that vascular pathology resulting in reduced cerebrovascular
reactivity contributes to frontocingulate hypoperfusion. Such pathology would impair
neurovascular coupling and reduce the ability of the vasculature to improve frontocingulate
perfusion during antidepressant treatment. Thus decreased cerebrovascular reactivity and
perfusion may be a biomarker of antidepressant nonresponse. As an initial step in this
research, the current study will utilize MRI arterial spin labeling (ASL) to examine if
cerebrovascular reactivity deficits and resting cerebral blood flow (CBF) deficits predict
antidepressant nonremission in LLD. The rationale for this proposal is that it will identify
mechanisms by which vascular pathology may contribute to LLD. If the study hypotheses are
correct, this crucial next step will support studies examining antidepressant properties of
cardiovascular drugs that may reverse vascular pathology and improve perfusion.
The investigators will pursue our initial goal by examining ASL predictors of nonremission
to a 12-week trial of sertraline. Forty LLD subjects will complete MRI, cognitive testing,
and hyperintensity assessment. ASL measured CBF will be obtained during a hypercapnia
challenge and at rest with room air. This will help determine if deficits in cerebrovascular
reactivity (CVR) and/or resting and on-demand CBF measures predict nonremission.
AIM: To test for differences in CVR and CBF in dorsal frontal cognitive control regions
between individuals who do and do not remit to a 12-week course of sertraline (defined as
MADRS ≤ 7).
Hypothesis 1: Compared with remitters, during a hypercapnia challenge nonremitters will
exhibit less CVR in the dlPFC and dAC.
Hypothesis 2: Compared with remitters, while breathing room air nonremitters will exhibit
lower resting CBF in the dorsal anterior cingulate (dAC) and dorsolateral prefrontal cortex
(dlPFC).
Exploratory Aim: To examine the relationship between ASL measures (CVR to hypercapnia and
resting CBF during normoxia) and performance in cognitive domains implicated in LLD
treatment outcomes. For this Aim, we will focus on functions involving the dlPFC and dAC,
specifically executive function and processing speed.
The study will enroll patients from clinical referrals and response to advertisements. In
these cases, potential participants will call our study contact number. Study staff will
describe the study to them, including a description of the study entry criteria. Those who
continue to be interested will then be scheduled for an evaluation. After scheduling, a
study physician will review their electronic medical record to assure that potential
subjects meet entry criteria.
Following policies of the Vanderbilt University Health System Institutional Review Board,
written informed consent will be obtained and documented by the study's Research Coordinator
before any study-related procedures are performed. The study coordinator will review study
procedures and the consent form with each potential participant. Each individual may take as
much time as they like to decide if they do or do not wish to participate. There is no
randomization. All participants receive open-label sertraline.
An initial evaluation will determine eligibility, depression severity, and evaluate medical
and psychiatric history. Participants will also complete a detailed battery assessing
cognitive function. During this time they will also complete the one-hour MRI session, which
includes measurement of cerebral perfusion and vascular reactivity.
They will then begin the 12-week trial of open-label sertraline, allowing titration up to
the maximum dose of 200mg daily. At the end of the study participants will be referred for
ongoing clinical treatment.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |